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https://doi.org/10.1053/j.gastro.2017.11.023BACKGROUND & AIMS: Clinical studies showed teduglutide
to increase urine production and reduce need for parenteral
support volume in patients with short bowel syndrome (SBS)
with intestinal failure, increasing intestinal wet weight
absorption and reducing diarrhea. However, the effects of
teduglutide on parenteral support vary among patients. We
performed a post hoc analysis of a phase III placebo-
controlled study to identify characteristics of patients in
whom teduglutide has the largest effects on parenteral
support volume response. METHODS: We collected data
from 85 patients with SBS with intestinal failure, according
to the European Society for Clinical Nutrition and Meta-
bolism classiﬁcation system, who received teduglutide or
placebo between November 25, 2008, and January 4, 2011,
at 27 sites in 10 countries. Changes in parenteral support
volume were evaluated according to baseline parenteral
support volume, bowel anatomy (group 1, jejunostomy/
ileostomy; group 2, 50% colon-in-continuity without
stoma; and group 3, other colon anatomies), and disease
features (with inﬂammatory bowel disease, mesenteric
vascular diseases, or other conditions). Correlation analyses
were conducted using simple linear regression models, with
unadjusted r2 values reported. Two-sided t tests were used
for comparisons between treatment groups. RESULTS: We
correlated parenteral support volume reduction with tedu-
glutide treatment and baseline parenteral support volume
(y ¼ –0.3870x þ 90.0279, r2 ¼ 0.61; P < .0001). The effects
of teduglutide on absolute parenteral support volume were
signiﬁcantly greater in group 1 patients (reduction of 919 ±
644 mL/d), not only compared with patients given placebo
(reduction of 340 ± 436 mL/d; P ¼ .0112) but also
compared with teduglutide-treated patients in group 2
(reduction of 355 ± 306 mL/d; P ¼ .0066). Teduglutide had
an intermediate effect on patients in group 3. A minority of
patients with SBS and inﬂammatory bowel diseases had
colon-in-continuity (10.5% [n ¼ 2/19]), whereas most
patients with SBS and vascular or other diseases had colon-
in-continuity (84.4% [n ¼ 27/32] and 67.6% [n ¼ 23/34],
respectively). CONCLUSIONS: In a post hoc analysis of data
from a phase III study of the effects of teduglutide on
patients with SBS, we associated reduced parenteral
support volume with baseline parenteral support volume,
bowel anatomy, and SBS features. These ﬁndings may inform
initial parenteral support volume adjustments and manage-
ment of these severely disabled patients. ClinicalTrials.gov
no: NCT00798967; ClinicalTrialsRegister.eu no: 2008-
006193-15.Keywords: Short-Gut Syndrome; GLP-2 Receptor Agonist;
Parenteral Nutrition; IBD.
eduglutide, a glucagon-like peptide-2 (GLP-2)Tanalog, is a novel drug approved for the treatment of
patients with short bowel syndrome (SBS) and intestinal
failure (IF).1,2 In the pivotal phase III, randomized, double-
blind, placebo-controlled study (ClinicalTrials.gov,
NCT00798967; ClinicalTrialsRegister.eu, 2008-006193-15),
63% of teduglutide-treated patients with IF who required
parenteral support (PS; parenteral nutrition and/or intra-
venous ﬂuids) 3 times per week for at least 12 months,
had a relative reduction in their PS volume of >20% (from
baseline at weeks 20 and 24) compared with 30% of
patients receiving placebo (P < .01).3 Due to a large
variation in patient response with respect to teduglutide-
induced PS volume changes, which ranged from –1993
to þ329 mL/d, this study aimed to identify characteristics of
individual patients with SBS who had the largest absolute
teduglutide-induced PS volume reductions.
GLP-2 receptor activation is known to prompt the
induction of crypt cell proliferation and prevention of
enterocyte apoptosis,4 leading to expansion of the epithelial
surface area and morphologic adaptation. However, recep-
tor activation also inhibits gastric acid secretion and gastric
emptying,5,6 stimulates intestinal blood ﬂow,7–9 increases
intestinal barrier function,10 opposes inﬂammatory
insults,11,12 and enhances nutrient and ﬂuid absorption.13–15
Theoretically, the teduglutide-induced amelioration of
the pathophysiologic manifestations of intestinal resection
contributing to the malassimilation would be more
pronounced in SBS–IF with an attenuated endogenous
postprandial GLP-2 secretion mainly seen in jejunostomy
SBS–IF.16 In contrast, in patients with SBS–IF with a
EDITOR’S NOTES
BACKGROUND AND CONTEXT
The glucagon-like peptide-2 analog, teduglutide, reduces
parenteral support (PS) volumes in patients with short
bowel syndrome–intestinal failure (SBS–IF). Because of
patient and treatment-effect heterogeneity, further
analyses are critical for individualized patient care.
NEW FINDINGS
Baseline PS volume strongly correlated with teduglutide-
associated PS volume reductions. Thus, in absolute
terms, SBS–IF patients with pronounced malabsorption
and high fecal losses are likely to beneﬁt the most from
teduglutide treatment.
LIMITATIONS
Because data are derived from a post hoc analysis, no
ﬁnal conclusions can be drawn regarding clinical
outcome, and randomized clinical trials are necessary to
corroborate the ﬁndings.
IMPACT
The ﬁndings may permit better individualization of initial PS
volume adjustments, thereby allowing patients to obtain
clinical beneﬁts from teduglutide more rapidly while
potentially alleviating ﬂuid accumulation side effects.
March 2018 Teduglutide Effects per ESPEN Classiﬁcations 875
CL
IN
IC
AL
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an elevated endogenous postprandial GLP-2 secretion, tedu-
glutide effects would theoretically be less pronounced.17
However, the preexisting condition leading to SBS–IF and the
severity of IF could also inﬂuence the effect of teduglutide.
Therefore, the aim of the current post hoc analysis
was to explore whether predictors of response regarding
absolute PS volume reduction in relation to teduglutide
treatment could be identiﬁed when grouping patients with
SBS–IF according to the principles set forth in the recent
European Society for Clinical Nutrition and Metabolism
(ESPEN)-endorsed classiﬁcations.18 Based on absolute PS
volume needs at baseline, the patients with IF were aligned
in the spectrum from borderline toward intestinal insufﬁ-
ciency across various degrees of IF.19 Separately, they were
grouped either according to bowel anatomy based on the
absence or presence of a stoma and/or a signiﬁcant amount
of colon-in-continuity (50%), or according to a diagnosis
classiﬁcation based on the original disease that caused the
intestinal resection (eg, mesenteric vascular disease [SBS–
Vasc], inﬂammatory bowel disease [SBS–IBD], or other
conditions). This allowed for the comparison of absolute PS
reductions in relation to teduglutide treatment in these
distinct pathophysiologic SBS–IF phenotypes.Methods
Patients and Study Design
Details regarding the key inclusion and exclusion criteria, as
well as a thorough description of the study design, have been
published previously.3 In summary, after screening, eligible
patients underwent a PS optimization period to achieve a stable
target urine output between 1.0 and 2.0 L per day. Eighty-sixpatients were randomized in a 1:1 ratio to teduglutide 0.05
mg/kg per day or placebo given subcutaneously once daily. All
patients were required to record PS volume, 48-hour oral ﬂuid
intake, and urinary output at baseline and before the post-
randomization evaluations. These visits were scheduled at
weeks 1, 2, 4, 8, 12, 16, 20, and 24. Reductions in PS volumes by
10% to 30% of baseline levels were allowed if the 48-hour
urinary volumes exceeded the baseline values by >10%. Oral
intakes during the 48-hour balances were intended to be con-
stant. Interim safety evaluations, including body weight and
laboratory tests, 1 week after PS reductions ensured that PS
reductions were well tolerated. The study was conducted in
accordance with the applicable International Conference on
Harmonisation Guidelines, Good Clinical Practice, and the
Declaration of Helsinki. The study protocol was approved by
local institutional review boards or medical ethics committees.
In the current exploratory analyses, the patients were pri-
marily categorized according to the severity of IF based on the
need for PS volume at baseline. Subsequently, patients were
classiﬁed according to bowel anatomy as follows: patients with
SBS–IF with a jejunostomy or ileostomy (group 1), patients with
SBS–IFwith50%of colon-in-continuity and no stoma (group 2),
and other colon anatomies (<50%colon orwith colostomy, group
3). Finally, patients were classiﬁed according to the underlying
condition that caused IF: SBS–IBD, SBS–Vasc, and other conditions
(Other). Thus, theentire studypopulationwas stratiﬁed3 timesby
baseline PS volume, by bowel anatomy, and by diagnosis to create
3 distinct analysis populations (ie, an individual patient was
independently assigned to each analysis population based on the
stratiﬁcation criteria of PS volume, bowel anatomy, or etiology).
Reduction in PS volume, reduction in oral ﬂuid intake, increase in
urine volume, and the ﬂuid composite effect (FCE), which repre-
sents the sum of these positive combined effects, were evaluated
according to these patient classiﬁcations.
Statistical Analysis
The intent-to-treat population consisted of 86 randomized
patients. One patient was randomized but discontinued before
the ﬁrst dose and did not undergo any study assessments. This
patient was excluded from the current post hoc analysis,
yielding an analysis population of 85.
Correlation analyses were conducted using simple linear
regression models; unadjusted r2 values are reported. Two-sided
t tests for 2 independent mean differences were used for
comparisons between patients receiving teduglutide vs those
receiving placebo. Generalization of P value interpretations may
be limited because of the small size of the analysis groups. Two
analysis of covariance (ANCOVA) models were evaluated, using
treatment arm (teduglutide or placebo) as the independent
variable and change in PS at week 24 as the dependent variable.
In the ﬁrst model, covariates were baseline PS volume and
remaining small bowel length. In the second model, covariates
were baseline PS volume, remaining small bowel length, and
diagnosis classiﬁcation. SAS version 9.3 (SAS Institute, Cary, NC)
was used for all statistical analyses. All authors had access to the
study data and reviewed and approved the ﬁnal manuscript.Results
In the overall SBS–IF patient population receiving
teduglutide, the average absolute PS volume reduction was
Figure 1. Absolute PS volume reduction at week 24 vs baseline PS volume in patients treated with teduglutide (A) or placebo
(B). þ symbol represents patients who became PS independent by the end of the 2-year, open-label extension of this phase III
study (NCT00930644; EudraCT 2009–011679–65).
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AT–625 ± 545 mL/d at week 24 compared with baseline vs
–327 ± 392 mL/d in patients receiving placebo (P ¼ .0072).
In patients with SBS–IF receiving placebo, the absolute
overall ﬂuid oral volume intake at week 24 compared with
baseline was higher vs those receiving teduglutide (226 ±
507 mL/d vs –25 ± 520 mL/d, respectively, P ¼ .036),
whereas the increase in urine output at week 24
compared with baseline was numerically higher in patients
receiving teduglutide (149 ± 296 mL/d) vs those receiving
placebo (40 ± 359 mL/d, not signiﬁcant vs baseline).
Consequently, the average reduction in FCE (ie, the sum of
reduction in PS volume, the reduction in oral ﬂuid intake,
and the increase in urine volume) was signiﬁcantly greater
at week 24 compared with baseline in patients receiving
teduglutide (–769 ± 851 mL/d) vs placebo (–153 ± 619
mL/d, P ¼ .0006).
When evaluating individual patient responses
(Figure 1A), a close, linear, and signiﬁcant correlation was
found between absolute PS volume reduction per day in
relation to teduglutide treatment and daily PS volume at
baseline (y ¼ –0.3870x þ 90.0279, r2 ¼ 0.61, P < .0001).
Thus, the patients with SBS–IF who required the highest PS
volumes at baseline had the largest absolute effects of tedu-
glutide on PS volume reduction. In patients receiving placebo
(Figure 1B), no signiﬁcant correlation was found between
absolute daily PS volume reduction and daily PS volume at
baseline (y¼ –0.0566x – 220.1419, r2 ¼ 0.02, P ¼ .36).
No signiﬁcant correlations were found between
reductions in oral intake (Figure 2A and B) or increases in
urine production (Figure 2C and D) and baseline PS volume
in patients receiving either teduglutide or placebo. However,
a close, linear, and signiﬁcant correlation was found
between the FCE in relation to teduglutide treatment
(Figure 2E) and daily PS volume at baseline in individual
patients with SBS–IF (y ¼ –0.4985x þ 125.9660, r2 ¼ 0.39,P < .0001). In patients receiving placebo (Figure 2F),
no signiﬁcant correlation was found between FCE and daily
PS volume at baseline (y ¼ –0.0686x – 24.3763, r2 ¼ 0.01,
P ¼ .49).
No correlation was found between remnant small bowel
length and PS volume change from baseline at week 24 in
either treatment group (r2 ¼ 0.0022 and P ¼ .7871 for
patients treated with teduglutide [n ¼ 36]; r2 ¼ 0.0086 and
P ¼ .5915 for patients treated with placebo [n ¼ 36]). After
correcting for remaining small bowel length in an ANCOVA
model, the effect of teduglutide on absolute PS volume
reduction at week 24 remained statistically signiﬁcant,
compared with placebo treatment (P ¼ .0025). To further
evaluate the effects of teduglutide in patients with various
anatomies, baseline patient characteristics stratiﬁed by
bowel anatomy classiﬁcation are provided in Table 1. In
spite of widespread interpatient heterogeneity regarding
baseline PS volume requirements, the patients with SBS–IF
with 50% colon-in-continuity and no ostomy (group 2;
indicated by symbol , in Figure 1) generally required
lower PS volumes at baseline compared with the jejunos-
tomy or ileostomy patients with SBS–IF without colon-in-
continuity (group 1; indicated by symbol B in Figure 1).
In group 2 as a whole, baseline PS volume was 1506 ± 777
mL/d, whereas baseline PS volume in group 1 was 2368 ±
1273 mL/d (P ¼ .001).
Table 2 provides the average bowel anatomy classiﬁca-
tion group outcomes and illustrates that in jejunostomy or
ileostomy patients with SBS–IF (group 1), the absolute
teduglutide-induced PS volume reductions were greater
(–919 ± 644 mL/d) not only compared with placebo (–340
± 436 mL/d, P ¼ .0112) but also compared with
teduglutide-treated patients with SBS–IF with 50% colon-
in-continuity and no ostomy (group 2; –355 ± 306 mL/d,
P ¼ .0066). In fact, in group 2 patients with SBS–IF, the
Figure 2. Absolute change in oral ﬂuid intake (A, B), urine volume (C, D), and ﬂuid composite effect (E, F) at week 24 vs baseline
PS volume in patients treated with teduglutide (A, C, E) or placebo (B, D, F). þ symbol represents patients who became PS
independent by the end of the 2-year, open-label extension of this phase III study (NCT00930644; EudraCT 2009-011679-65).
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Table 1.Baseline Patient Characteristics Stratiﬁed by Bowel Anatomy Classiﬁcation
Parameter
Group 1:
0% colon remaining
Stoma
No colon-in-continuity
Group 2:
50% colon remaining
No stoma
Colon-in-continuity
Group 3:
<50% colon
or with colostomy
TED (n ¼ 17) PBO (n ¼ 16) TED (n ¼ 18) PBO (n ¼ 20) TED (n ¼ 7) PBO (n ¼ 7)
Age, y, mean (SD) 52.1 (10.27) 50.7 (12.86) 51.3 (14.94) 50.3 (18.68) 49.6 (11.72) 46.0 (13.17)
Sex, n (%)
Male 8 (47.1) 7 (43.8) 9 (50.0) 10 (50.0) 3 (42.9) 2 (28.6)
Female 9 (52.9) 9 (56.3) 9 (50.0) 10 (50.0) 4 (57.1) 5 (71.4)
Body weight, kg, mean (SD) 66.3 (13.03) 62.3 (14.96) 61.0 (10.48) 62.2 (11.04) 58.6 (7.87) 59.1 (12.57)
BMI, kg/m2, mean (SD) 23.6 (3.63) 22.4 (3.24) 22.1 (2.86) 22.3 (3.02) 20.8 (2.05) 22.0 (3.62)
SBS history
Causes of SBS–IF, n (%)
Crohn’s disease 9 (52.9) 7 (43.8) 0 0 1 (14.3) 1 (14.3)
Vascular complications 3 (17.6) 2 (12.5) 10 (55.6) 13 (65.0) 2 (28.6) 2 (28.6)
Injury 1 (5.9) 3 (18.8) 3 (16.7) 1 (5.0) 0 0
Volvulus 0 0 2 (11.1) 4 (20.0) 1 (14.3) 2 (28.6)
Cancer 1 (5.9) 0 0 1 (5.0) 0 1 (14.3)
Other 3 (17.6)a 4 (25.0)b 3 (16.7)c 1 (5.0)d 3 (42.9)e 1 (14.3)f
Stoma present, n (%) 17 (100) 16 (100) 0 0 4 (57.1) 1 (14.3)
Jejunostomy 11 (64.7) 5 (31.3) 0 0 0 0
Ileostomy 6 (35.3) 9 (56.3) 0 0 0 0
Colostomy 0 0 0 0 4 (57.1) 1 (14.3)
Other 0 2 (12.5)g 0 0 0 0
Colon-in-continuity, n (%) 0 0 18 (100) 20 (100) 7 (100) 7 (100)
Estimated remaining small bowel length, cm, mean (SD) 137.7 (70.93)h 113.7 (79.76)h 52.2 (27.39) 39.2 (30.41)i 59.3 (44.39)j 49.3 (29.96)j
PS duration, y, mean (SD) 7.1 (6.73) 5.1 (3.07) 6.2 (6.45) 6.1 (6.44) 6.4 (5.64) 7.2 (8.24)
Number of PS days per week (actual based), mean (SD) 5.8 (1.54) 6.4 (1.14) 5.2 (1.60) 5.9 (1.49) 5.9 (1.59) 5.2 (1.68)
PS volume (actual based), mL/d, mean (SD) 2068.9 (1364.94) 2686.5 (1122.35) 1509.4 (827.31) 1502.9 (750.85) 1768.9 (1007.11) 1301.1 (552.18)
Oral volume intake, mL/d, mean (SD) 2186.5 (916.45) 1641.8 (591.78) 1567.0 (709.57) 1656.6 (649.07) 1990.2 (1043.00) 1572.4 (571.73)
Urine output, mL/d, mean (SD) 1237.8 (194.66) 1359.4 (268.90) 1478.9 (196.77) 1432.5 (285.47) 1290.4 (131.58) 1227.1 (172.79)
BMI, body mass index; IF, intestinal failure; PBO, placebo; TED, teduglutide.
aOther cause of SBS–IF ¼ radiation enteritis, ulcerative colitis, and ileus.
bOther cause of SBS–IF ¼ adhesions (n ¼ 2), mechanical ileus (n ¼ 1), and jejunal ﬁstula (n ¼ 1).
cOther cause of SBS–IF ¼ strangulated small intestine (n ¼ 2) and unspeciﬁed intestinal obstruction and peritoneal adhesions of intestine (n ¼ 1).
dOther cause of SBS–IF ¼ congenital intestinal atresia.
eOther cause of SBS–IF ¼ radiation enteritis, recurrent small bowel obstruction due to adhesions, and complications of hysterectomy.
fOther cause of SBS–IF ¼ familial adenomatous polyposis.
gOther stoma types ¼ duodenostomy (n ¼ 1) and jejunostomy and ileostomy (n ¼ 1).
hn ¼ 15.
in ¼ 19.
jn ¼ 6.
878
Jeppesen
et
al
Gastroenterology
Vol.154,No.4
CLINICALAT
Table 2.Change From Baseline at Week 24 in PS Volume, Days Off PS, Body Weight, FCE Components, and FCE Stratiﬁed by Bowel Anatomy Classiﬁcation
Parameter
Group 1:
0% colon remaining
Stoma
No colon-in-continuity
Group 2:
50% colon remaining
No stoma
Colon-in-continuity
Group 3:
<50% colon
or with colostomy
TED (n ¼ 17)a PBO (n ¼ 16) TED (n ¼ 18) PBO (n ¼ 20) TED (n ¼ 7) PBO (n ¼ 7)b
PS volume (actual based), change from
baseline, % change, mean (SD)
–40.3 (18.26) –18.8 (29.10)c –23.3 (15.84) –23.8 (22.23) –40.3 (18.75) –18.7 (30.88)
Additional days off PS per week, n (%)
1-day reduction at week 24 6 (42.9) 2 (15.4)c 10 (55.6) 6 (30.0) 5 (71.4) 1 (16.7)
2-day reduction at week 24 4 (28.6) 1 (7.7)c 2 (11.1) 2 (10.0) 2 (28.6) 0
3-day reduction at week 24 1 (7.1) 1 (7.7)c 1 (5.6) 1 (5.0) 2 (28.6) 0
Body weight change from baseline,
kg, mean (SD)
1.0 (4.15) 0.3 (2.61)c 0.2 (2.68) –1.1 (3.02) 3.0 (4.97) –0.7 (2.20)
Components of FCE change from
baseline, mL/d, mean (SD)
PS volume –919.3 (643.55)d –339.9 (435.67)c –354.8 (306.21) –327.2 (348.71) –728.4 (532.31) –297.4 (498.46)
Oral volume intake –248.7 (440.41) 239.8 (614.19)e 61.6 (571.65) 151.6 (440.58) 239.7 (364.39)b 448.1 (503.65)
Urine output 172.0 (236.19) 66.9 (570.06)e 76.6 (313.13) 47.1 (230.06) 307.9 (343.84)b 34.6 (167.48)
FCE change from baseline, mL/d, mean (SD) –1340.0 (992.79)f 204.9 (850.77)e –369.8 (577.13) –222.7 (306.21) –632.9 (397.38)b 185.3 (849.15)
PBO, placebo; TED, teduglutide.
an ¼ 14 with data available.
bn ¼ 6 with data available.
cn ¼ 13 with data available.
dP ¼ .0112 for comparison with patients treated with PBO in group 1, and P ¼ .0066 for comparison with patients treated with TED in group 2.
en ¼ 12 with data available.
fP ¼ .0044 for comparison with patients treated with PBO in group 1.
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ATeffect of teduglutide on PS volume reduction was not
signiﬁcantly different from that in patients receiving
placebo (–327 ± 349 mL/d, P ¼ .7964). Although group 1
patients experienced the greatest beneﬁts in terms of PS
volume reductions with teduglutide, all bowel anatomy
groups included a substantial proportion of patients who
obtained additional days per week off PS. As a result of the
combined positive effects of teduglutide (ie, the sum of the
reduction in PS volume, the reduction in oral volume intake,
and the increase in urine volume), a greater FCE reduction
of –1340 ± 993 mL/d was seen in teduglutide-treated
jejunostomy or ileostomy patients with SBS–IF (group 1)
compared with –205 ± 851 mL/d in patients treated with
placebo (P ¼ .0044). Again, no signiﬁcant difference was
detected between teduglutide- and placebo-treated
patients with SBS–IF with 50% colon-in-continuity
and no ostomy (group 2; –370 ± 577 vs –223 ± 306
mL/d, respectively; P ¼ .336). In patients with SBS–IF with
<50% colon-in-continuity or the presence of a colostomy
(group 3), the FCE effect of teduglutide was intermediate
(–633 ± 397 mL/d), whereas the average placebo effect
(185 ± 849 mL/d) resembled the placebo effect seen in
SBS–IF group 2. Group 1 patients were then further
divided into patients with jejunostomy (n ¼ 16) and
patients with ileostomy (n ¼ 15). Patients with jejunos-
tomy tended to have higher PS volume requirements at
baseline (teduglutide arm [n ¼ 11], 2455 ± 1463 mL/d;
placebo arm [n ¼ 5], 2557 ± 901 mL/d), compared with
patients with ileostomy (teduglutide arm [n ¼ 6], 1360 ±
866 mL/d; placebo arm [n ¼ 9], 2691 ± 1006 mL/d). With
24 weeks of teduglutide treatment, patients with jejunos-
tomy showed numerically greater reductions in PS volume
(–1058 ± 695 mL/d [n ¼ 10]) than did patients with
ileostomy (–572 ± 344 mL/d [n ¼ 4]). In contrast, patients
treated with placebo showed little change in PS volume at
week 24 in either the jejunostomy subgroup (–252 ± 407
mL/d [n ¼ 5]) or the ileostomy subgroup (–180 ± 296
mL/d [n ¼ 6]).
Baseline patient characteristics stratiﬁed by diagnosis
are provided in Table 3. Only a few of the patients with SBS–
IBD included in this study had a preserved colon-in-
continuity, whereas the presence of a colon was more
common in patients who had SBS–Vasc and SBS–IF due to
other conditions (Other; see bolded row in Table 3;
Figure 1A and B). Consequently, Table 4 illustrates that PS
volume reductions were greater in patients with SBS–IBD
treated with teduglutide (–1102 ± 654 mL/d) not only
compared with placebo-treated patients with SBS–IBD
(–357 ± 453 mL/d, P ¼ .0174) but also compared with
patients with SBS–Vasc (–513 ± 539 mL/d, P ¼ .0418)
and patients in the “Other” category (–450 ± 280 mL/d,
P ¼ .0168) receiving teduglutide. All etiology groups
included patients who obtained additional days per week off
PS, but teduglutide-induced FCE reduction was greater in
patients with SBS–IBD (–1437 ± 900 mL/d) not only
compared with patients with SBS–IBD treated with placebo
(27 ± 818 mL/d, P < .0168) but also compared with
patients with SBS–Vasc (–588 ± 995 mL/d, P < .0029);
signiﬁcance was not quite reached when these data werecompared with those of patients with other diagnoses
(–593 ± 444 mL/d, P ¼ .053).
An ANCOVA was conducted to evaluate the effect of
teduglutide on change from baseline in PS at week 24, while
controlling for baseline PS volume, remaining small bowel
length, and diagnosis classiﬁcation. The effect of teduglutide
remained signiﬁcant in the model (P ¼ .0026). In addition,
baseline PS volume had an independent effect on change
from baseline in PS volume (P < .0001). In contrast,
small bowel length and diagnosis classiﬁcation did not
independently inﬂuence change from baseline in PS at
week 24 (P ¼ .9387 and P ¼ .7077, respectively).Discussion
SBS is characterized by widespread patient heterogene-
ity.20 In addition, a large heterogeneity of response has been
described in relation to teduglutide treatment.21 Whereas
previous studies have primarily reported teduglutide
results based on group averages compared with placebo,
this hypothesis-generating, post hoc study aimed to identify
characteristics of individual patients with SBS or patient
groups in which teduglutide could provide an especially
favorable effect.
Previously, the classiﬁcation of patients with SBS has
mainly been based on the diagnosis leading to bowel
resection and the remnant bowel anatomy. However, it has
recently been suggested that the severity of IF be evaluated
based on the magnitude of the need for PS volume.18–20
When exploring the effect of teduglutide in post hoc
analyses based on these classiﬁcations, a signiﬁcant corre-
lation was found between absolute baseline PS volume
requirements and absolute PS volume reduction. Addition-
ally, in an ANCOVA model, baseline PS volume indepen-
dently predicted change in PS volume at week 24 in patients
treated with teduglutide. Thus, the patients with SBS–IF
with the poorest remnant bowel function, illustrated by
their need for a high volume of PS at baseline, experienced
the largest absolute effect of teduglutide on PS volume
reduction.
As illustrated in Figure 1A, anatomically, 5 of 6 patients
who experienced the largest PS volume reductions (1500
mL/d) in relation to teduglutide treatment had a jejunos-
tomy or ileostomy (group 1). In 5 of these 6 patients, IBD
was the cause of intestinal resection and SBS–IF. Five of 6
patients required PS volume>3000 mL/d. In general, only 2
of 19 patients with IBD included in this study had a remnant
part of their colon-in-continuity.
Both regression analysis and ANCOVA showed that
remaining small bowel length cannot be used to predict the
effects of teduglutide. In contrast, remnant bowel anatomy
appears to affect clinical response with teduglutide treat-
ment. Phenotypically, patients with jejunostomy or ileos-
tomy (group 1) are frequently characterized by accelerated
gastric emptying, gastric hypersecretion, and poor adapta-
tion following resection.19,22 As a consequence of the
resection of the terminal ileum and the colon, where the
L-cells are predominantly located, endogenous postprandial
GLP-2 secretion is likely to be compromised in patients with
Table 3.Baseline Patient Characteristics Stratiﬁed by Diagnosis Classiﬁcation
Parameter
SBS–IBD SBS–Vasc Other
TED (n ¼ 11) PBO (n ¼ 8) TED (n ¼ 15) PBO (n ¼ 17) TED (n ¼ 16) PBO (n ¼ 18)
Age, y, mean (SD) 48.2 (7.31) 48.0 (6.91) 52.3 (13.52) 56.7 (13.78) 52.6 (14.37) 43.9 (17.91)
Sex, n (%)
Male 6 (54.5) 3 (37.5) 9 (60.0) 8 (47.1) 5 (31.3) 8 (44.4)
Female 5 (45.5) 5 (62.5) 6 (40.0) 9 (52.9) 11 (68.8) 10 (55.6)
Body weight, kg, mean (SD) 66.6 (11.93) 62.5 (10.53) 63.9 (11.19) 66.6 (12.93) 59.0 (10.83) 56.7 (11.78)
BMI, kg/m2, mean (SD) 23.3 (4.08) 22.6 (3.56) 22.6 (3.43) 23.3 (3.36) 21.7 (2.14) 21.1 (2.34)
SBS history
Causes of SBS–IF, n (%)
Crohn’s disease 10 (90.9) 8 (100) 0 0 0 0
Vascular complications 0 0 15 (100) 17 (100) 0 0
Intestinal ischemia 5 (33.3) 4 (23.5)
Mesenteric vessel thrombi or emboli 9 (60.0) 13 (76.5)
Unknown vascular cause 1 (6.7) 0
Injury 0 0 0 0 4 (25.0) 4 (22.3)
Volvulus 0 0 0 0 3 (18.8) 6 (33.3)
Cancer 0 0 0 0 1 (6.3) 2 (11.1)
Other 1 (9.1)a 0 0 0 8 (50.0)b 6 (33.3)c
Stoma present, n (%) 11 (100) 7 (87.5) 4 (26.7) 2 (11.8) 6 (37.5) 8 (44.4)
Jejunostomy 8 (72.7) 1 (12.5) 2 (13.3) 1 (5.9) 1 (6.3) 3 (16.7)
Ileostomy 2 (18.2) 5 (62.5) 1 (6.7) 0 3 (18.8) 4 (22.2)
Colostomy 1 (9.1) 0 1 (6.7) 0 2 (12.5) 1 (5.6)
Other 0 1 (12.5)d 0 1 (5.9)e 0 0
Colon-in-continuity, n (%) 1 (9.1) 1 (12.5) 12 (80.0) 15 (88.2) 12 (75.0) 11 (61.1)
Estimated remaining small bowel length, cm, mean (SD) 128.9 (77.01) 127.8 (98.34) 70.9 (57.77) 40.2 (29.90) 75.9 (55.01) 67.6 (49.95)
PS duration, y, mean (SD) 8.1 (7.95) 7.2 (7.40) 5.5 (4.71) 6.1 (6.19) 6.6 (6.55) 5.1 (4.47)
Number of PS days per week (actual based), mean (SD) 5.7 (1.60) 6.6 (1.24) 5.6 (1.47) 5.4 (1.68) 5.4 (1.72) 6.2 (1.13)
PS volume (actual based), mL/d, mean (SD) 2267.5 (1480.49) 3087.7 (1156.25) 1826.7 (982.12) 1338.0 (730.66) 1398.8 (811.29) 1927.9 (855.07)
Oral volume intake, mL/d, mean (SD) 2456.4 (1175.90) 1521.4 (531.76) 1779.7 (761.25) 1633.9 (536.42) 1599.5 (575.34) 1692.2 (707.56)
Urine output, mL/d, mean (SD) 1160.0 (160.42) 1301.6 (242.99) 1384.5 (251.50) 1389.3 (326.49) 1447.9 (113.99) 1386.7 (225.86)
BMI, body mass index; PBO, placebo; TED, teduglutide.
aOther cause of SBS–IF ¼ ulcerative colitis.
bOther cause of SBS–IF ¼ radiation enteritis (n ¼ 2), strangulated small intestine (n ¼ 2), ileus (n ¼ 1), recurrent small bowel obstruction due to adhesions (n ¼ 1),
complications of hysterectomy (n ¼ 1), and unspeciﬁed intestinal obstruction and peritoneal adhesions of intestine (n ¼ 1).
cOther cause of SBS–IF ¼ adhesions (n ¼ 2), mechanical ileus (n ¼ 1), congenital intestinal atresia (n ¼ 1), familial adenomatous polyposis (n ¼ 1), and jejunal ﬁstula (n ¼ 1).
dOther stoma type ¼ duodenostomy.
eOther stoma type ¼ jejunostomy and ileostomy.
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Table 4.Change From Baseline at Week 24 in PS Volume, Days Off PS, Body Weight, FCE Components, and FCE Stratiﬁed by Diagnosis Classiﬁcation
Parameter
SBS–IBD SBS–Vasc Other
TED (n ¼ 11) PBO (n ¼ 8)a TED (n ¼ 15) PBO (n ¼ 17) TED (n ¼ 16)b PBO (n ¼ 18)c
PS volume (actual based), change from
baseline, % change, mean (SD)
–45.2 (18.29)d –11.4 (14.57) –24.9 (18.42) –25.2 (34.48)c 32.2 (16.42) –21.8 (17.36)
Additional days off PS per week, n (%)
1-day reduction at week 24 3 (33.3)d 0 8 (53.3) 5 (31.3)c 10 (66.7) 4 (25.0)
2-day reduction at week 24 2 (22.2)d 0 3 (20.0) 3 (18.8)c 3 (20.0) 0
3-day reduction at week 24 1 (11.1)d 0 2 (13.3) 2 (12.5)c 1 (6.7) 0
Body weight change from baseline,
kg, mean (SD)
2.2 (5.41)d 1.5 (2.66) 0.4 (3.15) 1.5 (3.41)c 0.9 (3.20) –0.5 (1.48)
Components of FCE change from
baseline, mL/d, mean (SD)
PS volume –1101.7 (653.66)d,e –357.1 (453.15) –512.6 (539.17) –277.4 (428.26)c –450.1 (280.06) –363.0 (345.27)
Oral volume intake –220.3 (337.92)f 246.1 (608.02) –23.9 (500.12) 187.5 (530.73)b 79.0 (611.10) 253.9 (470.17)
Urine output 190.6 (179.81)f –138.2 (238.53) 51.8 (285.63) 30.9 (242.63)b 222.1 (341.47) 127.5 (465.62)
FCE change from baseline, mL/d,
mean (SD)
–1436.5 (900.14)f,g 27.2 (818.38) –588.3 (995.07) –146.9 (574.79)b –593.2 (443.71) –236.6 (587.73)
PBO, placebo; TED, teduglutide.
an ¼ 7 with data available.
bn ¼ 15 with data available.
cn ¼ 16 with data available.
dn ¼ 9 with data available.
eP ¼ .0174 for comparison with patients treated with PBO in the SBS–IBD group, P ¼ .0418 for comparison with patients treated with TED in the SBS–Vasc group, and
P ¼ .0168 for comparison with patients treated with TED in the “Other” group.
fn ¼ 8 with data available.
gP < .0168 for comparison with patients treated with PBO in the SBS–IBD group, P < .0029 for comparison with patients treated with TED in the SBS–Vasc group, and
P ¼ .053 for comparison with patients treated with TED in the “Other” group.
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ATjejunostomy or ileostomy.16 It is possible that jejunostomy
or ileostomy patients with the shortest remnant bowels,
particularly those with the largest ileal resections, would
have the smallest endogenous, fasting, and postprandial
GLP-2 feedback signal. Therefore, jejunostomy patients
would experience the most accelerated gastric emptying
and gastric hypersecretion as well as the poorest mucosal
stimulation for adaptive growth. Accordingly, these patients
would experience the most pronounced beneﬁts from
supplementation of the exogenous GLP-2 analog teduglu-
tide. In fact, among the jejunostomy or ileostomy patients
with SBS–IF (group 1) in this study, a signiﬁcant correlation
was demonstrated between remnant small bowel length
and the need for PS volume at baseline; those with the
shortest remnant bowels had the highest PS volume needs
(y ¼ –7.8571x þ 3459.7501 [where y is PS volume in
mL/d at baseline and x is small bowel length in cm],
r2 ¼ 0.21, P ¼ .01). Furthermore, when we divided group 1
into jejunostomy and ileostomy subgroups, the jejunostomy
subgroup showed greater reductions in PS volume with
teduglutide than both the ileostomy subgroup and group 1
as a whole, consistent with the premise that this subgroup
includes patients with the least endogenous GLP-2 signaling
and therefore beneﬁts most from teduglutide treatment.
Endogenous postprandial GLP-2 secretion was not
measured in patients included in this study to support this
hypothesis.
As anticipated, the well-known beneﬁts from the ﬂuid-,
electrolyte-, and energy-salvaging effects of the colon could
be demonstrated in the patients with SBS–IF in this study
who had a substantial colon-in-continuity (50%) and no
ostomy (group 2).23–25 Thus, in spite of having signiﬁcantly
shorter average small bowel lengths (Table 1) compared
with the jejunostomy or ileostomy patients with SBS–IF
(group 1), these group 2 patients had signiﬁcantly lower
baseline PS volume needs (group 1: 2368 ± 1273 mL/d vs
group 2: 1506 ± 777 mL/d, P ¼ .001). None of these group
2 patients suffered from IBD, and most (22 of 38) suffered
from mesenteric vascular complications leading to SBS–IF.
Consequently, only 1 of the 38 patients in group 2 had a
need for PS volume exceeding 3000 mL/d. It is likely that
the provision of PS volume in many of these patients was
mainly to provide parenteral energy rather than ﬂuid and
electrolytes. However, the composition of PS volume content
(parenteral energy vs ﬂuid and electrolytes) was not
investigated in this study.
The absolute effect of teduglutide on PS volume reduc-
tion in group 2 patients was signiﬁcantly less pronounced
when compared with group 1. Thus, a PS volume reduction
>500 mL/d was observed in only 4 of 18 patients in group
2 treated with teduglutide. The maximal effect of teduglu-
tide on PS volume reduction was 964 mL/d (1 patient in
group 2). Equivalently, a PS volume reduction >500 mL/d
was demonstrated in 6 of 20 patients in group 2 receiving
placebo, suggesting that effects of teduglutide on PS volume
reduction were in fact limited in most patients with SBS–IF
with this anatomy. Thus, compared with placebo, no effect
of teduglutide was seen in group 2 patients with regard toPS volume reduction or changes in the FCE at the time of
this evaluation. The effects of teduglutide on intestinal
energy absorption were not measured in this study.
Phenotypically, patients with SBS–IF who have a
substantial part of the colon in the absence of a stoma are
frequently characterized by a more typical pattern of gastric
emptying and gastric acid secretion, and good structural
and functional adaptation compared with patients with
jejunostomy or ileostomy. Apart from the ﬂuid-, electrolyte-,
and energy-salvaging effects of the preserved colon, these
patients may beneﬁt from a preserved or even elevated
endogenous hormone secretion and neuroendocrine feed-
back signaling from the distal to the proximal gastrointes-
tinal tract,17,26,27 although endogenous hormonal secretion
was not measured in this study. Indeed, many of these
group 2 patients with SBS–IF spontaneously adapt and are
gradually weaned from PS in the years following their
midbowel resection.28 This is also illustrated by the fact that
patients with SBS–IF with this particular anatomy are rare
and frequently constitute <25% of the patients in adult IF
cohorts in centers with aggressive PS weaning programs.20
Although the effect of teduglutide seems limited with
regard to PS volume reduction in the well-adapted group
2 patients with SBS–IF with >50% colon-in-continuity and
no ostomy who may already have beneﬁted from their
preserved endogenous GLP-2 secretion, it is not clear
whether teduglutide could accelerate early post resectional
adaptation. In metabolic balance studies, it has been
demonstrated that teduglutide improves intestinal energy
absorption by approximately 1 MJ/d in these patients.21
Because the algorithm for PS reductions was based on
increases in urine volume reﬂecting reductions in fecal wet
weight losses and increases in intestinal wet weight
absorption, PS volume weaning was modest and late in
these patients. However, in the open-label extension studies,
in which weaning policies were more liberal, the beneﬁt on
energy absorption may have been clinically appreciated,
leading to the provision of days off PS or even PS weaning in
some of these patients.
Patients with SBS–IF in group 3 either had <50% colon-
in-continuity, a colostomy, or both. On average, the effect of
teduglutide on PS volume reduction was somewhat inter-
mediate (728.4 ± 532.3 mL/d) compared with groups 1 and
2. This may reﬂect the fact that the anatomy of these
patients was less beneﬁcial with regard to the ﬂuid-,
electrolyte-, and energy-salvaging effects of a relatively
shorter colon and perhaps weaker adaptive neuroendocrine
feedback signaling.
Although remnant bowel anatomy appears to affect the
clinical response in terms of absolute reductions in PS
volume, patients in all bowel anatomy groups obtained
additional days off PS per week with teduglutide treatment.
Even in the context of lower baseline and absolute PS
volume reductions, most patients in bowel anatomy groups
2 and 3 were able to obtain 1 additional PS-free day per
week with teduglutide treatment.
In conclusion, ﬁndings from these post hoc analyses
suggest that the effect of teduglutide on improving ﬂuid
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the need for PS volume is highly variable among patients
with SBS–IF. In general, the greater absolute effects of
teduglutide on PS volume reduction were seen in patients
with SBS–IF with higher baseline PS volume requirements.
These were mainly patients with SBS–IF with jejunos-
tomies or ileostomies, and in this study, most of these
patients suffered from IBD. The more rapid and pro-
nounced effects of teduglutide on intestinal ﬂuid
absorption in these jejunostomy or ileostomy patients with
high PS volume requirements should alert clinicians to
more careful monitoring and rapid adjustment of PS
volume prescriptions, preferably guided according to
standard protocols resembling the original study proced-
ures. By performing simple ﬂuid balance studies,
measuring changes in body weight, and surveying con-
ventional biochemistry, it may be possible to minimize the
inconveniences of ﬂuid retention related to the introduc-
tion of teduglutide in some patients with SBS–IF. Thereby,
these patients may be able to reduce jejunostomy or
ileostomy output while simultaneously reducing the need
for PS volume, thereby reducing or at best eliminating
the inconveniences of PS infusions. The effect of teduglu-
tide on PS volume reductions was lower in patients
with SBS–IF with >50% colon-in-continuity and no
colostomy and in patients with <50% remaining colon-in-
continuity or a colostomy. These ﬁndings show that a
signiﬁcant knowledge regarding the SBS–IF patient
heterogeneity and heterogeneity of response to teduglu-
tide treatment is required to provide the best individual-
ized care for these patients suffering from a rare organ
failure disease.References
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